by Raynovich Rod | May 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update August 5, 2014 Large Cap Biopharmaceutical Stocks Includes Q1 Earnings Reports (except REGN due 5/8) Rayno Focus Picks: ALXN, AMGN, BIIB, FBT, GILD, REGN, RHHBY Large cap stocks are core holdings especially now that sector momentum is easing. ABBV dropped...
by Raynovich Rod | Apr 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85) up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno...
by Raynovich Rod | Apr 21, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Have A Strong Day-April 15 Bottom Holding Rayno Life Science Portfolios Stick with larger caps through earnings: ABBV, AMGN, ALKS, BIIB, GILD. MOMO mid cap stocks coming back today: INCY MDVN PBYI plus many others. Losers- Cepheid (CPHD and...
by Raynovich Rod | Apr 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Apr 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 4/10 Abrupt Sell-Off –Failure to Confirm Bottom NASDAQ down 71 pts 1.7% All of yesterdays’ gains wiped out and we are back to January levels. Raise cash levels to 30% on life science portfolios. Many high fliers and core holdings are selling off...
by Raynovich Rod | Apr 8, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To...
by Raynovich Rod | Apr 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the...
by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Mar 17, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three...
by Raynovich Rod | Mar 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
March 17 Update -GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%,...
